Catalyst Wire Dossier Catalyst Wire Dossier

GSK malaria vaccine (candidate, co-administered with measles, rubella and yellow fever vaccines)

unknown · GlaxoSmithKline
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GSK malaria vaccine (candidate, co-administered with measles, rubella and yellow fever vaccines), covering 2019-08-29 to 2019-08-29. Get the full timeline:

Most recent: Clinical Trial Update: Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine. [Phase 3]

See pricing